CMS Proposal On Part D May Address Drug Costs, But Will It Target Prices?
Executive Summary
Upcoming proposed rule on Medicare Part D and Medicare Advantage prompts speculation about whether CMS is planning new measures to control spending on prescription drugs.
You may also be interested in...
HHS Leadership Upheaval Could Delay Initiatives Impacting Biopharma
Secretary Price will be succeeded on an acting basis by HHS acting assistant secretary for health Donald Wright, and everything from development of the executive order on drug pricing to pending Medicare reimbursement experiments could see a pause as part of the transition.
Medicare Part D Rebate Pass-Throughs To Beneficiaries Is 'On The Table'
Lilly CEO David Ricks reflects on the state of play on drug pricing issues on Capitol Hill and in the Administration and the challenges he sees ahead.
Closing The Spread: 340B Providers Face Sharp Cuts Under Medicare Proposal
Medicare payments to hospitals for drugs provided under the 340B program would be reduced to average sales price (ASP) minus 22.5%, which CMS believes is more closely aligned with the discounted price obtained by the providers.